» Articles » PMID: 21824982

The Role of the Endocannabinoid System in the Neuroendocrine Regulation of Energy Balance

Overview
Publisher Sage Publications
Specialty Pharmacology
Date 2011 Aug 10
PMID 21824982
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Animal and human studies carried out so far have established a role for the endocannabinoid system (ECS) in the regulation of energy balance. Here we critically discuss the role of the endocannabinoid signalling in brain structures, such as the hypothalamus and reward-related areas, and its interaction with neurotransmitter and neuropeptide systems involved in the regulation of food intake and body weight. The ECS has been found to interact with peripheral signals, like leptin, insulin, ghrelin and satiety hormones and the resulting effects on both central and peripheral mechanisms affecting energy balance and adiposity will be described. Furthermore, ECS dysregulation has been associated with the development of dyslipidemia, glucose intolerance and obesity; phenomena that are often accompanied by a plethora of neuroendocrine alterations which might play a causal role in determining ECS dysregulation. Despite the withdrawal of the first generation of cannabinoid type 1 receptor (CB1) antagonists from the pharmaceutical market due to the occurrence of psychiatric adverse events, new evidence suggests that peripherally restricted CB1 antagonists might be efficacious for the treatment of obesity and its associated metabolic disorders. Thus, a perspective on new promising strategies to selectively target the ECS in the context of energy balance regulation is given.

Citing Articles

Higher Plasma Levels of Endocannabinoids and Analogues Correlate With a Worse Cardiometabolic Profile in Young Adults.

Di X, Martinez-Tellez B, Krekels E, Jurado-Fasoli L, Osuna-Prieto F, Ortiz-Alvarez L J Clin Endocrinol Metab. 2023; 109(5):1351-1360.

PMID: 37967236 PMC: 11031222. DOI: 10.1210/clinem/dgad668.


Anandamide and 2-arachidonoylglycerol baseline plasma concentrations and their clinical correlate in gambling disorder.

Baenas I, Sole-Morata N, Granero R, Fernandez-Aranda F, Pujadas M, Mora-Maltas B Eur Psychiatry. 2023; 66(1):e97.

PMID: 37937379 PMC: 10755577. DOI: 10.1192/j.eurpsy.2023.2460.


Effects of cannabidiol on weight and fasting blood sugar with chronic and subchronic haloperidol administration.

Kajero J, Seedat S, Ohaeri J, Akindele A, Aina O Discov Ment Health. 2023; 2(1):18.

PMID: 37861864 PMC: 10501030. DOI: 10.1007/s44192-022-00021-2.


Association of anandamide and 2-arachidonoylglycerol concentrations with clinical features and body mass index in eating disorders and obesity.

Baenas I, Miranda-Olivos R, Granero R, Sole-Morata N, Sanchez I, Pastor A Eur Psychiatry. 2023; 66(1):e49.

PMID: 37254556 PMC: 10305007. DOI: 10.1192/j.eurpsy.2023.2411.


The function of the endocannabinoid system in the pancreatic islet and its implications on metabolic syndrome and diabetes.

Cortes-Justo E, Garfias-Ramirez S, Vilches-Flores A Islets. 2023; 15(1):1-11.

PMID: 36598083 DOI: 10.1080/19382014.2022.2163826.